Analysts Set Expectations for MREO FY2026 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Mereo BioPharma Group in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.08) for the year. Cantor Fitzgerald has a "Overweight" rating and a $7.00 price target on the stock. The consensus estimate for Mereo BioPharma Group's current full-year earnings is ($0.03) per share.

Several other analysts have also issued reports on the stock. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, May 13th. JPMorgan Chase & Co. began coverage on shares of Mereo BioPharma Group in a report on Thursday, March 27th. They issued an "overweight" rating and a $7.00 price objective on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of "Buy" and an average target price of $7.67.

Mereo BioPharma Group Trading Down 0.7%

MREO traded down $0.02 on Wednesday, hitting $2.76. The company had a trading volume of 1,235,452 shares, compared to its average volume of 1,099,907. The firm has a market cap of $438.84 million, a P/E ratio of -39.43 and a beta of 0.47. Mereo BioPharma Group has a 1 year low of $1.58 and a 1 year high of $5.02. The company's fifty day moving average price is $2.36 and its 200 day moving average price is $2.77.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01).

Institutional Trading of Mereo BioPharma Group

A number of institutional investors and hedge funds have recently bought and sold shares of MREO. Newbridge Financial Services Group Inc. purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $37,000. HealthInvest Partners AB increased its stake in Mereo BioPharma Group by 95.0% during the fourth quarter. HealthInvest Partners AB now owns 390,000 shares of the company's stock worth $1,373,000 after purchasing an additional 190,000 shares during the period. Sheets Smith Investment Management purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $59,000. XTX Topco Ltd purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $133,000. Finally, Walleye Capital LLC purchased a new stake in Mereo BioPharma Group during the fourth quarter worth about $454,000. 62.83% of the stock is currently owned by hedge funds and other institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.